Publikationen in Zusammenarbeit mit Forschern von University of Münster (42)

2024

  1. Evolution of spontaneous portosystemic shunts over time and following aetiological intervention in patients with cirrhosis

    JHEP Reports, Vol. 6, Núm. 2

2023

  1. A plain language summary of the impact of vaccines against flu and chickenpox in people with multiple sclerosis treated with cladribine tablets

    Neurodegenerative Disease Management, Vol. 13, Núm. 1, pp. 15-21

  2. Expert opinion on COVID-19 vaccines and cladribine tablets in MS: A plain language summary

    Neurodegenerative Disease Management, Vol. 13, Núm. 1, pp. 5-13

  3. Expert opinion on the long-term use of cladribine tablets for multiple sclerosis: Systematic literature review of real-world evidence

    Multiple Sclerosis and Related Disorders, Vol. 69

  4. Sympathetic nervous activation, mitochondrial dysfunction and outcome in acutely decompensated cirrhosis: the metabolomic prognostic models (CLIF-C MET)

    Gut, Vol. 72, Núm. 8, pp. 1581-1591

2022

  1. Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data

    Multiple Sclerosis Journal, Vol. 28, Núm. 5, pp. 842-846

  2. Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores

    Journal of the National Cancer Institute, Vol. 114, Núm. 1, pp. 109-122

  3. Efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis with suboptimal response to prior disease-modifying therapies: A primary analysis from the phase 3b CASTING single-arm, open-label trial

    European Journal of Neurology, Vol. 29, Núm. 3, pp. 790-801

  4. Platelet number and function alterations in preclinical models of sterile inflammation and sepsis patients: implications in the pathophysiology and treatment of inflammation

    Transfusion and Apheresis Science, Vol. 61, Núm. 2

  5. The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021

    Multiple sclerosis (Houndmills, Basingstoke, England), Vol. 28, Núm. 9, pp. 1424-1456

  6. Varicella zoster virus and influenza vaccine antibody titres in patients from MAGNIFY-MS who were treated with cladribine tablets for highly active relapsing multiple sclerosis

    Multiple Sclerosis Journal

2021

  1. Expert opinion on COVID-19 vaccination and the use of cladribine tablets in clinical practice

    Therapeutic Advances in Neurological Disorders, Vol. 14

  2. Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study

    The Lancet Neurology, Vol. 20, Núm. 1, pp. 49-59

2020

  1. A Network of Macrophages Supports Mitochondrial Homeostasis in the Heart

    Cell, Vol. 183, Núm. 1, pp. 94-109.e23

  2. Association of genomic domains in BRCA1 and BRCA2 with prostate cancer risk and aggressiveness

    Cancer Research, Vol. 80, Núm. 3, pp. 624-638

  3. Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk

    Scientific reports, Vol. 10, Núm. 1, pp. 9688

2019

  1. Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer

    Nature Communications, Vol. 10, Núm. 1

  2. Large scale multifactorial likelihood quantitative analysis of BRCA1 and BRCA2 variants: An ENIGMA resource to support clinical variant classification

    Human Mutation, Vol. 40, Núm. 9, pp. 1557-1578

  3. Predictors of disease worsening defined by progression of organ damage in diffuse systemic sclerosis: A European Scleroderma Trials and Research (EUSTAR) analysis

    Annals of the Rheumatic Diseases, Vol. 78, Núm. 9, pp. 1242-1248

  4. Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the european scleroderma trials and research (eustar) cohort

    Annals of the Rheumatic Diseases, Vol. 78, Núm. 5, pp. 648-656